PMID- 8392345
OWN - NLM
STAT- MEDLINE
DCOM- 19930811
LR  - 20061115
IS  - 0004-4172 (Print)
IS  - 0004-4172 (Linking)
VI  - 43
IP  - 5
DP  - 1993 May
TI  - Comparison of low molecular weight heparins and unfractionated heparin after 
      successive subcutaneous administration. A randomized controlled study in healthy 
      volunteers.
PG  - 542-7
AB  - The biological response to 4 different heparins after successive subcutaneous 
      administration once daily for 5 days at a dose used for primary prophylaxis of 
      deep vein thrombosis was investigated in a randomized cross-over study in 12 
      volunteers. Three different preparations of low molecular weight heparins (LMWH) 
      were administered, 10,000 U unfractionated heparin (UFH) was used as a control. 
      The anticoagulant properties in terms of anti-Xa activities, as measured by a 
      chromogenic substrate assay or Heptest, showed high interindividual variations 
      with peak levels 2 to 4 h following injections. There was a significantly higher 
      increase of anti-Xa activities 3 h after administration at day 5, when compared 
      with day 1, for two LMWH's, suggesting an accumulation of the anticoagulatory 
      effect. The anticoagulant activity, especially when measured by Heptest, was 
      significantly influenced by the body weight. This could be observed for all 
      LMWH's. For the assessment of anticoagulant activity in LMWH-treated individuals, 
      the chromogenic substrate assay and Heptest revealed maximal correlation (r = 
      0.51), while in UFH-treated individuals, peak correlation (r = 0.75) was observed 
      between the partial thromboplastin time and thrombin clotting time. The 
      chromogenic substrate method was the most sensitive anti-Xa assay, showing also 
      the smallest interindividual variation. No significant influence of heparins 
      neither on platelet count and function nor on fibrinolysis were recognized. 
      Enhanced lipolytic activities were not observed. There was an increase of alanine 
      aminotransferases induced by UFH as well as LMWH's, which, however, was most 
      pronounced after UFH.
FAU - Pindur, G
AU  - Pindur G
AD  - Abteilung fur Klinische Hamostaseologie und Transfusionsmedizin, 
      Universitatskliniken des Saarlandes, Homburg/Saar, Fed. Rep. of Germany.
FAU - Heiden, M
AU  - Heiden M
FAU - Kohler, M
AU  - Kohler M
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Germany
TA  - Arzneimittelforschung
JT  - Arzneimittel-Forschung
JID - 0372660
RN  - 0 (Anticoagulants)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 9005-49-6 (Heparin)
RN  - EC 2.6.1.2 (Alanine Transaminase)
RN  - EC 3.4.21.6 (Factor Xa)
SB  - IM
MH  - Adult
MH  - Alanine Transaminase/blood
MH  - Anticoagulants/*pharmacology
MH  - Factor Xa/*metabolism
MH  - Female
MH  - Hemostasis/drug effects
MH  - Heparin/administration & dosage/adverse effects/*pharmacology
MH  - Heparin, Low-Molecular-Weight/administration & dosage/adverse 
      effects/*pharmacology
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Male
MH  - Middle Aged
EDAT- 1993/05/01 00:00
MHDA- 1993/05/01 00:01
CRDT- 1993/05/01 00:00
PHST- 1993/05/01 00:00 [pubmed]
PHST- 1993/05/01 00:01 [medline]
PHST- 1993/05/01 00:00 [entrez]
PST - ppublish
SO  - Arzneimittelforschung. 1993 May;43(5):542-7.